These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16913035)

  • 1. The changing perspective on breast cancer and chemotherapy. Three new developments are better able to predict breast cancer recurrence and chemotherapy effectiveness.
    Health News; 2006 Aug; 12(8):14-5. PubMed ID: 16913035
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemoprevention of breast cancer: recommendations and rationale.
    Berg AO;
    Am J Nurs; 2003 May; 103(5):107, 109, 111, 113. PubMed ID: 12759615
    [No Abstract]   [Full Text] [Related]  

  • 3. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point.
    Jordan VC
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2207-9. PubMed ID: 18006908
    [No Abstract]   [Full Text] [Related]  

  • 4. Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint.
    Fabian C
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2210-2. PubMed ID: 18006909
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemoprevention of breast cancer: recommendations and rationale.
    Am Fam Physician; 2003 Mar; 67(6):1309-14. PubMed ID: 12674459
    [No Abstract]   [Full Text] [Related]  

  • 6. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
    Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
    Lyman GH; Cosler LE; Kuderer NM; Hornberger J
    Cancer; 2007 Mar; 109(6):1011-8. PubMed ID: 17311307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current status of breast cancer chemoprevention: a star is born.
    Morrow M; Jordan VC
    J Surg Oncol; 2007 Jan; 95(1):4-5. PubMed ID: 17192883
    [No Abstract]   [Full Text] [Related]  

  • 9. The Study of Tamoxifen and Raloxifene (STAR trial) for the prevention of breast cancer.
    Kelminski A
    Hawaii Med J; 2002 Sep; 61(9):209-10. PubMed ID: 12422387
    [No Abstract]   [Full Text] [Related]  

  • 10. Tamoxifen treatment and new-onset depression in breast cancer patients.
    Lee KC; Ray GT; Hunkeler EM; Finley PR
    Psychosomatics; 2007; 48(3):205-10. PubMed ID: 17478588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?
    Peppercorn J; A Carey L
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):191-4. PubMed ID: 18279059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs.
    Vastag B
    J Natl Cancer Inst; 2006 Jun; 98(11):733-5. PubMed ID: 16757696
    [No Abstract]   [Full Text] [Related]  

  • 16. A better option?
    Gorman C
    Time; 2006 May; 167(18):70. PubMed ID: 16689077
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
    Toi M; Yamashiro H; Tsuji W
    Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?
    McCaul KA
    Obstet Gynecol; 2005 Jan; 105(1):217-8; author reply 218-9. PubMed ID: 15625169
    [No Abstract]   [Full Text] [Related]  

  • 19. [Breast cancer chemoprevention. Rational, trials results and future].
    Cutuli B; Lesur A; Namer M; Kerbrat P
    Bull Cancer; 2009 May; 96(5):519-30. PubMed ID: 19467983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cerebrovascular risks associated with tamoxifen use.
    Bushnell C
    Expert Opin Drug Saf; 2005 May; 4(3):501-7. PubMed ID: 15934856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.